Discovery of SU086 as an inhibitor of glycolysis and a potential treatment strategy for advanced prostate cancer

The Stoyanova Lab discovers that SU086, an HSP90 inhibitor, inhibits glycolysis and exhibits therapeutic potential in advanced prostate cancer. Congratulations Meghan and team!

https://pubmed.ncbi.nlm.nih.gov/35243415/